| Product: | Chlorambucil | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Catalog Number: | 17416 | ||||||||
| CAS Number: | 305-03-3 | ||||||||
| Synonyms: | 4-(4-[Bis(2-chloroethyl)amino]phenyl)butyric acid; 4-[Bis(2-chloroethyl)amino]benzenebutyric acid | ||||||||
| Pricing: |
| ||||||||
| Formula: | C14H19Cl2NO2 | ||||||||
| Molecular Weight: | 304.21 | ||||||||
| Structure: |  | ||||||||
| Appearance: | Beige powder | ||||||||
| Category: | Anti-cancer compounds | ||||||||
| Stability: | Stable under recommended storage conditions. | ||||||||
| Storage: | Keep container tightly closed in a dry and well-ventilated place. Recommended storage temperature: 2-8°C. | ||||||||
| Transportation: | IATA: Hazard Class: 6.1; UN Number: UN2811; Packing Group: III; Shipping Name: Toxic solids, organic, n.o.s. (Chlorambucil) | ||||||||
| Literature References: | Muller, C., et al., DNA-Dependent protein kinase activity correlates with clinical and in vitro sensitivity of chronic lymphocytic leukemia lymphocytes to nitrogen mustards. Blood 92, 2213-2219, (1998); Morrow, C.S., et al., Coordinated action of glutathione S-transferases (GSTs) and multidrug resistance protein 1 (MRP1) in antineoplastic drug detoxification. J. Biol. Chem. 273, 20114-20120, (1998); Morabito, F., et al., Bcl-2 protein expression and p53 gene mutation in chronic lymphocytic leukemia: correlation with in vitro sensitivity to chlorambucil and purine analogs. Haematologica 82, 16-20, (1997); Panasci, L., et al., Chlorambucil drug resistance in chronic lymphocytic leukemia: the emerging role of DNA repair. Clin. Cancer Res. 7, 454-461, (2001); Merck 14,2073; Beil. 14,IV,1715 | ||||||||
| MSDS: | |||||||||
| Description: | Chlorambucil is an anti-cancer drug that alkylates DNA and induces apoptosis. Death of chronic lymphocytic leukemia cells occurs via a p53-dependent mechanism |
